United States

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549  

 

Form 6-K

 

 

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16

OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the Month of April, 2018

 

Commission File Number: 001-35892  

 

GW PHARMACEUTICALS PLC

(Translation of registrant’s name into English)

 

Sovereign House

Vision Park

Histon

Cambridge CB24 9BZ

United Kingdom

(Address of principal executive offices)

 

 

 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

 

Form 20-F  x   Form 40-F  ¨

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

 

Yes  ¨   No  ¨

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):

 

Yes  ¨   No  ¨

 

 

 

 

  

Notification of Interests of Directors, Officers and Connected Persons

 

GW Pharmaceuticals plc (the “Company”) hereby provides notification that on March 27, 2018, Julian Gangolli, President of the Company’s US Operations, exercised options under the Company’s Long Term Incentive Plan and sold 1,110 American Depositary Shares (“ADSs”) at a price of $114.56 per ADS in accordance with his Rule 10b5-1 plan established March 13, 2018. Further details are set forth in the table below.

 

1. Details of the person discharging managerial responsibilities / person closely associated
a. Name Julian Gangolli
2. Reason for the notification
a. Position/status President of GW’s US Operations
b.

Initial notification

/Amendment

Initial notification
3. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a. Name GW Pharmaceuticals PLC
b. LEI  
4. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a.

Description of the

Financial instrument, type of instrument

Identification code

 

American Depositary Shares

ISIN: 36197T1034

b. Nature of the transaction Sell to cover transaction resulting in exercise of Long Term Incentive Plan options over 3,183 American Depositary Shares (ADSs) followed by sale of 1,110 ADSs in accordance with 10b5.1 plan dated 13 March 2018 to cover tax liability. Remaining 2,073 ADSs have been retained.

c. Price(s) and volume(s)  Price(s) 
$114.56
Volume(s)
1,110

ADS’s sold

d.

Aggregated information

¨ Aggregated volume

¨ Price

 

 

n/a

e. Date of the transaction 27 March 2018
f. Place of the transaction Nasdaq, New York

 

 

For further information, please contact:

 

GW Pharmaceuticals PLC +44 (0)1980 557 000

Adam George, Company Secretary

 

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

  GW Pharmaceuticals plc
     
  By: /s/ Adam George
  Name:   Adam George
  Title:   Company Secretary
     
Date: April 3, 2018    

 

 

Ways to keep up to date with GW